Wells Fargo lowered the firm’s price target on Health Catalyst (HCAT) to $6 from $10 and keeps an Overweight rating on the shares. The firm sees top-line pressure as largely margin-neutral, and notes that cut revenue is either low-margin or offset by cost savings. Wells’ adjusted EBITDA outlook is essentially unchanged.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst’s Strategic Restructuring and Cost Management Justify Buy Rating Despite Revenue Guidance Reduction
- Health Catalyst downgraded to Neutral from Buy at Citi
- Health Catalyst downgraded to Neutral from Overweight at Cantor Fitzgerald
- Health Catalyst Reports Strong Q2 2025 Results
- Health Catalyst CEO Dan Burton to step down effective June 2026